Biovaxys Technology Corp (BVAXF)

$0.05 0.00 (-3.60%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 35,800
Avg Vol 120,112
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 85%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
NewMexicats
NewMexicats May. 1 at 9:00 PM
$BVAXF
0 · Reply
wheresdannynow
wheresdannynow May. 1 at 8:40 PM
Volume doesn’t lie. $BIOV.CSE $BVAXF just printed ~627k and ~505k back-to-back, roughly 4–6x average. That’s not random for a sub-$3M market cap name.
0 · Reply
FLArnot
FLArnot May. 1 at 7:35 PM
$BVAXF This stock is either going to be one to tell your grandkids about, or a total bust. I really don't see an in-between with this one. Of course I am voting for the grandkids story.
2 · Reply
Davidendz
Davidendz May. 1 at 5:28 PM
Immunotherapy momentum continuing to build, especially around checkpoint inhibitor combinations. $MRK (Keytruda) leading the space, with $BMY $AZN also competing in PD-1 / PD-L1. Now $BIOV.CSE $BVAXF adding more validation with MVP-S + checkpoint inhibitors + low-dose cyclophosphamide showing strong immune response signals in ovarian cancer. Durability stands out, responses lasting up to 3 years, and immune activation tied directly to disease control. This is where platform + combination therapy narratives start getting attention.
0 · Reply
NewMexicats
NewMexicats May. 1 at 4:58 PM
$BVAXF Seems kind weird the Nature article was published on 4/9/2026 but they didn't do the Press Release until today. I guess they were busy? Lol. The rigorously peer reviewed article appeared in "Nature Imaging" because it tracked the DPX mechanism using MRI, rather than Nature Cancer for example. It's really about how DPX works.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 1 at 3:10 PM
Nature/NPJ Imaging just published peer reviewed DPX science. same combination as PESCO trial. tumor volume down, immune cells up. filings delayed but the science keeps validating. that gap between fundamentals and attention is exactly where this sits. $BIOV $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 1 at 3:00 PM
Nature/NPJ Imaging April 2026 published. Dr. Kimberly Brewer of Dalhousie University used MRI to track tumor growth and immune response in ovarian cancer using MVP-S plus anti-PD-1 plus cyclophosphamide. same combination as the PESCO trial. tumor volume significantly lowered, immune cells increased. independent peer reviewed validation of the platform. audit is delayed, science is not. $BIOV $BVAXF https://investingnews.com/biovaxys-presents-further-validation-of-the-robust-immune-response-from-a-combination-of-mvp-s-with-checkpoint-inhibitors-and-low-dose-cyclophosphamide-in-ovarian-cancer/
0 · Reply
Ventureville
Ventureville May. 1 at 12:14 PM
Immunotherapy momentum still building across the sector. $MRK $BNTX $MRNA driving large-cap validation, but platform-based smaller caps tend to follow once attention rotates. $BIOV.CSE $BVAXF sits in that lane with DPX showing continued activity across indications. Filings delay noted, but no red flags beyond timing. Science continues to progress in the background. That gap between fundamentals and attention is where moves usually start.
0 · Reply
NewMexicats
NewMexicats Apr. 30 at 9:31 PM
$BVAXF https://x.com/i/status/2049912602726150342 The stars are aligning. Publication in the Nature Family is huge.
3 · Reply
ProfitWhisperer
ProfitWhisperer Apr. 30 at 5:17 PM
clean update, no new issues. just auditor timing. ASCO PESCO data coming May 29. market waiting on admin to clear while the science keeps moving. $BIOV $BVAXF
1 · Reply
Latest News on BVAXF
No data available.
NewMexicats
NewMexicats May. 1 at 9:00 PM
$BVAXF
0 · Reply
wheresdannynow
wheresdannynow May. 1 at 8:40 PM
Volume doesn’t lie. $BIOV.CSE $BVAXF just printed ~627k and ~505k back-to-back, roughly 4–6x average. That’s not random for a sub-$3M market cap name.
0 · Reply
FLArnot
FLArnot May. 1 at 7:35 PM
$BVAXF This stock is either going to be one to tell your grandkids about, or a total bust. I really don't see an in-between with this one. Of course I am voting for the grandkids story.
2 · Reply
Davidendz
Davidendz May. 1 at 5:28 PM
Immunotherapy momentum continuing to build, especially around checkpoint inhibitor combinations. $MRK (Keytruda) leading the space, with $BMY $AZN also competing in PD-1 / PD-L1. Now $BIOV.CSE $BVAXF adding more validation with MVP-S + checkpoint inhibitors + low-dose cyclophosphamide showing strong immune response signals in ovarian cancer. Durability stands out, responses lasting up to 3 years, and immune activation tied directly to disease control. This is where platform + combination therapy narratives start getting attention.
0 · Reply
NewMexicats
NewMexicats May. 1 at 4:58 PM
$BVAXF Seems kind weird the Nature article was published on 4/9/2026 but they didn't do the Press Release until today. I guess they were busy? Lol. The rigorously peer reviewed article appeared in "Nature Imaging" because it tracked the DPX mechanism using MRI, rather than Nature Cancer for example. It's really about how DPX works.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 1 at 3:10 PM
Nature/NPJ Imaging just published peer reviewed DPX science. same combination as PESCO trial. tumor volume down, immune cells up. filings delayed but the science keeps validating. that gap between fundamentals and attention is exactly where this sits. $BIOV $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 1 at 3:00 PM
Nature/NPJ Imaging April 2026 published. Dr. Kimberly Brewer of Dalhousie University used MRI to track tumor growth and immune response in ovarian cancer using MVP-S plus anti-PD-1 plus cyclophosphamide. same combination as the PESCO trial. tumor volume significantly lowered, immune cells increased. independent peer reviewed validation of the platform. audit is delayed, science is not. $BIOV $BVAXF https://investingnews.com/biovaxys-presents-further-validation-of-the-robust-immune-response-from-a-combination-of-mvp-s-with-checkpoint-inhibitors-and-low-dose-cyclophosphamide-in-ovarian-cancer/
0 · Reply
Ventureville
Ventureville May. 1 at 12:14 PM
Immunotherapy momentum still building across the sector. $MRK $BNTX $MRNA driving large-cap validation, but platform-based smaller caps tend to follow once attention rotates. $BIOV.CSE $BVAXF sits in that lane with DPX showing continued activity across indications. Filings delay noted, but no red flags beyond timing. Science continues to progress in the background. That gap between fundamentals and attention is where moves usually start.
0 · Reply
NewMexicats
NewMexicats Apr. 30 at 9:31 PM
$BVAXF https://x.com/i/status/2049912602726150342 The stars are aligning. Publication in the Nature Family is huge.
3 · Reply
ProfitWhisperer
ProfitWhisperer Apr. 30 at 5:17 PM
clean update, no new issues. just auditor timing. ASCO PESCO data coming May 29. market waiting on admin to clear while the science keeps moving. $BIOV $BVAXF
1 · Reply
ProfitWhisperer
ProfitWhisperer Apr. 30 at 5:08 PM
defined timeline now. May 31 filings, ASCO May 29. audit delay stings but the overhang clears once it lands. science keeps moving in the background. $BIOV $BVAXF
0 · Reply
Ventureville
Ventureville Apr. 30 at 3:24 PM
$BIOV.CSE $BVAXF still working through filings, now targeting May 31. Delay is there, but update stayed clean, no red flags beyond timing. At the same time, ASCO PESCO acceptance brings fresh ovarian cancer data, and MVP-S continues to show durability. DPX platform keeps doing its job. Market just waiting on the admin side to clear.
0 · Reply
FLArnot
FLArnot Apr. 29 at 8:48 PM
$BVAXF Everyone to their own opinion, but I read the delay as positive... I just don't want it to spill over into a trade halt like 2024.
0 · Reply
Davidendz
Davidendz Apr. 29 at 6:53 PM
Reading the room on $BIOV.CSE $BVAXF pushing filings to May 31. Not ideal, but update stayed clean, no red flags beyond the delay. Meanwhile, ASCO PESCO acceptance adds fresh ovarian cancer immune-response data. DPX platform keeps delivering on the science while admin catches up. That disconnect tends to close.
0 · Reply
ProfitWhisperer
ProfitWhisperer Apr. 29 at 6:33 PM
April 28 missed, May 31 is the new target. auditor needs more time, company confirmed no insolvency. meanwhile melanoma LOI submitted with Dalhousie and Sona last night, fourth cancer type added. ASCO presentation Chicago May 29. frustrating delay but the science keeps moving. $BIOV $BVAXF
0 · Reply
wheresdannynow
wheresdannynow Apr. 29 at 5:54 PM
Reading the room on $BIOV.CSE $BVAXF pushing filings to May 31, not ideal, but the update was clean, no new issues flagged.
0 · Reply
Ventureville
Ventureville Apr. 29 at 1:17 PM
$BIOV.CSE $BVAXF still in MCTO status, but timeline now defined with filings targeted by end of May. That matters. Market doesn’t price uncertainty well, but once filings land, that overhang clears. At the same time, clinical pipeline still active, MVP-S, PESCO, broader DPX platform. Structure + science both in play. Quiet setup while attention is elsewhere.
0 · Reply
Albertacrude
Albertacrude Apr. 28 at 7:49 PM
$BVAXF https://x.com/biovaxys/status/2049198231360589953?s=12&t=GDQ_fezLQJW8B7SHdiIHmw
0 · Reply
Johndoe1979
Johndoe1979 Apr. 28 at 6:47 PM
$BVAXF https://x.com/i/status/2049198231360589953
0 · Reply
Albertacrude
Albertacrude Apr. 28 at 5:40 PM
$BVAXF only 35 million shares in the float , one deal sends it to the daq
0 · Reply
FLArnot
FLArnot Apr. 28 at 4:52 PM
$BVAXF
1 · Reply
FLArnot
FLArnot Apr. 28 at 4:49 PM
$BVAXF
0 · Reply